Clinical Trial Detail

NCT ID NCT03556228
Title Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors VM Oncology, LLC
Indications

thymoma

Advanced Solid Tumor

triple-receptor negative breast cancer

pancreatic cancer

thymic carcinoma

lymphoma

Therapies

VMD-928

Age Groups: senior adult

No variant requirements are available.